Manages Credentials in Highly Regulated Pharmaceutical Industry
LOS GATOS, Calif., Oct. 22 /PRNewswire/ -- TriCipher today joined the SAFE(TM) (Signatures and Authentication for Everyone) BioPharma Association Vendor Partner Program, pledging to promote the adoption of the SAFE standards through the company's user and transaction authentication solutions. SAFE-approved credentials will seamlessly operate on TriCipher Armored Credential System (TACS), the company's strong authentication platform leveraging a variety of multi-factor credentials.
The industry group gives TriCipher access to forward-thinking corporate users of digital information processing, such as Amgen, AstraZeneca, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. By agreeing to credentialing standards, these companies reduce the cost and time for pharmaceutical companies to advance drug development and deploy new business processes.
SAFE provides the industry's legal foundation for digital signatures and user authentication across pharmaceutical companies. Its standards are legally enforceable because they ensure user authentication, digital document integrity and auditable non-repudiation of users' actions.
"The pharmaceutical industry sets the bar for other industries with highly regulated and valuable online activities," said John De Santis, TriCipher's CEO. "SAFE and TriCipher make it possible to get more business value out of strong authentication credentials, increasing profits and better serving customers with faster product development and lower costs."
TriCipher, Inc. provides a unified authentication infrastructure to
protect web and enterprise portals, the people that use them and the
business process that flows through them against fraud and identity theft.
The TriCipher Armored Credential System(TM) (TACS) is the first
authentication system that enab
|SOURCE TriCipher, Inc.|
Copyright©2007 PR Newswire.
All rights reserved